

GPZL Leadership Team Meeting

1 July 2021 | 13:00 - 14:00 CET

Participants

Leadership team members and guests

- Benedict Quao, Program Manager, National Leprosy Elimination Program of Ghana
- Bill Simmons (Chair), President & CEO, American Leprosy Missions
- Deanna Hagge, Senior Research Advisor, The Leprosy Mission (TLM)
- Erwin Cooreman, Team Leader, WHO Global Leprosy Programme
- Geoff Warne, CEO, International Federation of Anti-Leprosy Associations (ILEP)
- Maarten van Cleeff, Former Director of Challenge TB project, KNCV
- Mauricio Lisboa Nobre, Consultant to Brazilian Leprosy Programme
- Takahiro Nanri, Executive Director, Sasakawa Health Foundation

Secretariat

- Andie Tucker, Project Manager, Global Partnership for Zero Leprosy
- Bill Gallo, Secretariat Director, Global Partnership for Zero Leprosy
- Caroline Cassard, Communications Specialist, Global Partnership for Zero Leprosy
- Mondie Tharp, Project Manager, Global Partnership for Zero Leprosy

Invited but unable to attend

- Alice Cruz, UN Special Rapporteur
- Amar Timalina, President, International Association for Integration, Dignity and Economic Advancement (IDEA) Nepal
- Arielle Cavaliero, Global Franchise Lead, Leprosy, Novartis
- Gangadhar Sunkara, Senior Global Program Clinical Head, Novartis
- Linda Hummel, Chair of Executive Group, Leprosy Research Initiative (LRI)
- Rao Pemmaraju, Technical Officer, WHO Global Leprosy Programme
- Rekha Shukla, Joint Secretary, Ministry of Health and Family Welfare, India
- Roch Christian Johnson, President, International Leprosy Association
- Wim van Brakel, Chair, ILEP Technical Commission (ITC)

Summary of Key Decisions / Action Items

- **Action Item** – Diagnostic Working Group will discuss a third use case.
- **Action Item** – Country Model Working Group will incorporate suggestions from the LT.

Meeting Agenda

Presenter	Item
Bill Simmons	I. Welcome
Andie Tucker	II. Leprosy Diagnostic Target Product Profile Update
Erik Post Carol Tangum Mondie Tharp	III. Country Model Working Group Update a. Country model development, M&E plan development, country model working group b. Q&A
Bill Simmons	IV. AOB
Meeting Notes	
Meeting Objective	Notes
Update: Leprosy Diagnostic Target Product Profile	<p>Group convened experts under WHO DTAG to develop 2 use cases which were drafted into TPPs:</p> <ol style="list-style-type: none"> 1. Diagnostic test to confirm the diagnosis of leprosy in individuals with clinical signs and symptoms, target product profile 2. A diagnostic test to detect Mycobacterium leprae infection among asymptomatic household/familial contacts of leprosy patients to treat them with appropriate prophylactic interventions and prevent the occurrence of overt clinical leprosy. <p>Next steps:</p> <ol style="list-style-type: none"> 1. TPP is currently undergoing internal review with DTAG. 2. Working group will discuss potential third use case 3. TPPs: connecting with product developers <ol style="list-style-type: none"> a. Janssen/Johnson & Johnson medical research & pharmaceutical product development reached out because they are developing a diagnostic for an upcoming trial and want to create something that could have utility for the leprosy community, if possible 4. Projected timeline: 2 months
Update: Country Model Working Group	<p>Country Model Working Group</p> <ul style="list-style-type: none"> ● Persons affected should be engaged in the Country Model Working Group. <p>Country Model Tools</p> <ul style="list-style-type: none"> ● Request for more information about GLP “critical actions” linked to Pillar 4 (Combat stigma and ensure human rights are respected). <p>M&E</p> <ul style="list-style-type: none"> ● Need for sensitive language: Receiving a Tier I classification could offend the Ministry. ● Tier II includes “Proportion of patients with worsening disability grade during MDT treatment.” This indicator should account for when disability starts. Some

	<p>programmes may not have this data, but it is possible to get data during MDT and post-MDT. Indicators should be integrated.</p> <ul style="list-style-type: none"> ● The level of endemicity is not always linked to the strength of a programme. We need to classify the programme and endemicity separately. ● Consider including the average age of patients. This number would help with monitoring because you would see a shift to the right for older ages. ● Consider the difficulty in collecting data for coverage and screening rates.
AOB	<p>In the meeting following the Mozambique review, we could invite external experts and/or the NLPM who supported the country review to discuss.</p>
<p>Key Upcoming Dates</p>	
<ul style="list-style-type: none"> ● Next Meeting: 5 August 2021 at 13:00 CET - https://emory.zoom.us/j/96051181681 	